imspire 150: atezolizumab, cobimetinib and vemurafenib in untreated patients with brafv600 mutat...
Published 3 years ago • 190 plays • Length 6:36Download video MP4
Download video MP3
Similar videos
-
2:24
biomarker analysis of cobrim: phase 3 trial of cobimetinib plus vemurafenib for advanced melanoma
-
3:33
cobimetinib plus vemurafenib for advanced braf-mutated melanoma
-
6:58
triplet therapies for advanced metastatic melanoma
-
6:48
vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma
-
2:36
hamid: cobimetinib, zelboraf for previously untreated melanoma
-
1:17
cobimetinib and atezolizumab in colorectal cancer
-
2:21
dr. omid hamid on vemurafenib and atezolizumab in melanoma
-
3:12
cobimetinib and atezolizumab vs pembrolizumab for advanced melanoma
-
7:58
regulatory approvals for vemurafenib/cobimetinib, necitumumab, and elotuzumab
-
3:40
brim8: vemurafenib in high risk melanoma patients
-
4:49
vemurafenib for high risk melanoma patients
-
2:40
key outcomes of the phase 1b of atezolizumab and bevacizumab for advanced hcc
-
3:33
the co-brim study: quality-of-life assessment in patients with metastatic melanoma
-
1:08
dr. weber on dabrafenib/trametinib versus vemurafenib/cobimetinib in melanoma
-
2:38
dr. mittendorf highlights fda approval of atezolizumab/nab-paclitaxel in pd-l1 tnbc
-
0:31
preview: fda approvals in cll and all, nda accepted in melanoma, and more
-
4:22
melanoma immunotherapy latest and tvec plus pembrolizumab
-
24:18
pembrolizumab is better than ipilimumab for advanced melanoma in phase iii trial